Compare IOSP & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | GRDN |
|---|---|---|
| Founded | 1938 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Retail-Drug Stores and Proprietary Stores |
| Sector | Industrials | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1998 | 2024 |
| Metric | IOSP | GRDN |
|---|---|---|
| Price | $78.89 | $30.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $124.00 | $32.00 |
| AVG Volume (30 Days) | ★ 307.3K | 290.1K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | ★ $1,789,200,000.00 | $1,389,638,000.00 |
| Revenue This Year | N/A | $19.50 |
| Revenue Next Year | $5.06 | $0.48 |
| P/E Ratio | ★ N/A | $109.91 |
| Revenue Growth | N/A | ★ 18.68 |
| 52 Week Low | $70.10 | $17.78 |
| 52 Week High | $117.08 | $37.43 |
| Indicator | IOSP | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 65.21 | 59.22 |
| Support Level | $77.40 | $29.73 |
| Resistance Level | $79.29 | $31.50 |
| Average True Range (ATR) | 1.74 | 1.09 |
| MACD | 0.53 | 0.08 |
| Stochastic Oscillator | 88.97 | 71.56 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.